Medicenna Therapeutics Corp. MDNA.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -41.47% | -55.07% | 52.31% | 49.25% | 51.06% |
| Total Depreciation and Amortization | 5.85% | 37.47% | 116.93% | 328.03% | 725.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 47.88% | 45.34% | -167.97% | -155.51% | -161.21% |
| Change in Net Operating Assets | 74.76% | 183.44% | 562.12% | 970.24% | 25.54% |
| Cash from Operations | -7.16% | -9.58% | -10.38% | 1.63% | -13.61% |
| Capital Expenditure | -- | -- | 100.00% | 100.00% | 93.39% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 193.33% | 105.79% | 105.79% | 100.00% | 93.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -143.75% | -273.68% | -- | -- | -- |
| Issuance of Common Stock | 31.39% | -99.78% | -99.78% | -91.05% | -85.81% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 100.00% | -- |
| Cash from Financing | 45.55% | -100.08% | -100.07% | -91.36% | -87.59% |
| Foreign Exchange rate Adjustments | 310.53% | -173.34% | -184.22% | 2,469.40% | -138.58% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.77% | -327.52% | -332.47% | -410.06% | -354.92% |